Henry Schein, Inc. (NASDAQ:HSIC) EVP Mark E. Mlotek sold 10,359 shares of the company’s stock in a transaction dated Tuesday, June 12th. The stock was sold at an average price of $72.73, for a total value of $753,410.07. Following the sale, the executive vice president now owns 79,506 shares in the company, valued at approximately $5,782,471.38. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of Henry Schein traded up $0.56, reaching $72.89, during mid-day trading on Thursday, according to Marketbeat.com. The company’s stock had a trading volume of 65,458 shares, compared to its average volume of 1,782,942. Henry Schein, Inc. has a 12-month low of $62.56 and a 12-month high of $93.24. The company has a market cap of $11.21 billion, a P/E ratio of 20.19, a PEG ratio of 1.73 and a beta of 1.00. The company has a debt-to-equity ratio of 0.34, a quick ratio of 0.74 and a current ratio of 1.44.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, May 8th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.03. Henry Schein had a return on equity of 19.68% and a net margin of 3.18%. The business had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.18 billion. During the same quarter in the prior year, the business posted $0.88 EPS. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. analysts predict that Henry Schein, Inc. will post 4.1 earnings per share for the current fiscal year.

Several equities research analysts have weighed in on HSIC shares. ValuEngine downgraded Henry Schein from a “sell” rating to a “strong sell” rating in a report on Wednesday, May 2nd. Leerink Swann upgraded Henry Schein from a “market perform” rating to an “outperform” rating and set a $75.00 price target on the stock in a report on Wednesday, April 4th. BidaskClub downgraded Henry Schein from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Barrington Research restated an “outperform” rating on shares of Henry Schein in a report on Wednesday, February 21st. Finally, JPMorgan Chase & Co. restated a “neutral” rating and set a $77.00 price target (down previously from $79.00) on shares of Henry Schein in a report on Thursday, February 15th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $81.59.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Suntrust Banks Inc. increased its holdings in shares of Henry Schein by 27.8% in the 1st quarter. Suntrust Banks Inc. now owns 20,079 shares of the company’s stock valued at $1,349,000 after acquiring an additional 4,371 shares during the last quarter. Allianz Asset Management GmbH increased its holdings in shares of Henry Schein by 14.3% in the 1st quarter. Allianz Asset Management GmbH now owns 584,528 shares of the company’s stock valued at $39,286,000 after acquiring an additional 73,176 shares during the last quarter. Polar Asset Management Partners Inc. purchased a new position in shares of Henry Schein in the 1st quarter valued at about $12,306,000. Amalgamated Bank increased its holdings in shares of Henry Schein by 9.7% in the 1st quarter. Amalgamated Bank now owns 22,884 shares of the company’s stock valued at $1,538,000 after acquiring an additional 2,017 shares during the last quarter. Finally, CIBC World Markets Inc. increased its holdings in shares of Henry Schein by 174.1% in the 1st quarter. CIBC World Markets Inc. now owns 13,005 shares of the company’s stock valued at $874,000 after acquiring an additional 8,261 shares during the last quarter. Institutional investors and hedge funds own 96.65% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.